---
run_id: halo-evidence-vs-diagnosis-validation-v8-substrate-workflow-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: substrate_workflow
run_number: 8
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 803
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
condition_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
output_file: model-outputs/substrate_workflow-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `substrate_workflow`, run 8 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 803, on the frozen condition packet.

## Output

I recommend that you advise the CEO to **run the targeted evidence pass**.

### Reasoning
The current "upbeat story" presented to the board is a textbook instance of the **Halo Effect** (BK-0048-card-001). The rise in net revenue retention and the faster renewals have created a general impression of success, which is now driving leadership to re-describe previously criticized behaviors—such as being "bespoke" and "reactive"—as "customer-obsessed" and "disciplined." Because the performance signal (revenue) is visible, the trait assessment is contaminated; the team hasn't actually become more disciplined, the observer's perception has simply shifted to fit the positive outcome.

Furthermore, the company is currently confusing "execution targets" with **Validated Learning** (BK-0007-card-001). The revenue bump is largely artificial (72% driven by discounts), and the usage spike is driven by "champions" rather than the front-line reviewers who actually determine the product's value. The fact that 69% of front-line reviewers abandon the tool after one week and insurance accounts find it unusable for audits indicates that the product has not yet achieved validated learning.

Scaling now (Option 1) would be a "Bad Strategy" because it lacks a **Kernel** (BK-0001-card-001). It offers a list of coherent actions (hires, integrations, quota expansion) but lacks a valid **diagnosis**. A diagnosis based on halo-tinted revenue data is not a diagnosis; it is a reflection of a temporary financial anomaly. Narrowing the plan immediately (Option 3) is also premature, as it pivots the company based on a partial signal (the insurance segment) without first determining if the "explainability" issue is a universal blocker or a segment-specific one.

The targeted evidence pass is the only option that treats the current situation as a high-uncertainty environment requiring empirical evidence of customer behavior to form a real strategic diagnosis.

### The Strongest Reason Against
**Political and Budgetary Risk.** The board locks the budget in twelve days and is currently enamored with an "upbeat story." Recommending a "pause" on discounts and a "targeted evidence pass" will be perceived as a lack of confidence or a sudden deceleration. By stripping away the "halo" and the artificial revenue boosters, you are effectively telling the CEO and the board that the current success is an illusion, which may jeopardize the funding and headcount requested for the coming year.

### Observable Evidence That Would Change My Mind
I would change this recommendation to "Scale Broadly" only if the **front-line reviewer retention rate** (currently 31%) showed a statistically significant increase across multiple segments *independent* of the strategic-feature pitch and discounts. If the data showed that the "champions" were successfully onboarding front-line users who then stayed active without financial incentives, it would indicate that the product has moved from a "vanity" success to a "validated" one, providing a sound diagnosis for scaling.
